Core Viewpoint - The Gross Law Firm is notifying shareholders of Kyverna Therapeutics, Inc. regarding a class action lawsuit related to the company's initial public offering (IPO) in February 2024, alleging misleading statements and omissions in the offering documents [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals who purchased or acquired Kyverna common stock during the class period associated with the February 2024 IPO [3]. - Allegations include that the defendants issued materially false and misleading statements and failed to disclose critical information regarding the IPO strategy, terms, and disclosures in the offering documents [4]. - The complaint suggests that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal representatives [4]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 7, 2025, to participate in potential recovery [5]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [5]. - There is no cost or obligation for shareholders to participate in the lawsuit [5]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].
The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – KYTX